Background Renal dysfunction and Fanconi's syndrome associated with hypophosphatemia caused by long-term administration of low-dose adefovir dipivoxil (ADV) has been reported in recent years. The aim of this retrospective study was to determine the incidence and factors associated with renal dysfunction and hypophosphatemia in patients with hepatitis B infection on long-term treatment with ADV and lamivudine (LAM). Methods The study subjects were 292 patients treated with 10 mg/day ADV and 100 mg/day LAM for more than 6 months. We evaluated estimated glomerular filtration rate (eGFR), serum creatinine and serum phosphate level at the start of ADV and every 6 months. Result During a median treatment duration of 64 months, 28 (9.6 %) patients developed renal impairment (defined as eGFR \ 50 ml/min/1.73 m 2 ), and 73 (27.1 %) developed hypophosphatemia, including 14 with persistent hypophosphatemia. The cumulative incidences of renal impairment at 1, 3, and 5 years were 1.4, 7.5, 10.5 %, respectively, and those of hypophosphatemia were 6.8, 20.6, 26.7 %, respectively. Multivariate analysis identified old age, liver cirrhosis and hypertension as determinants of renal impairment, and male sex, HCC, low baseline serum phosphate as determinants of hypophosphatemia. Three of the 14 patients with persistent hypophosphatemia developed Fanconi's syndrome; their serum creatinine level remained normal, but eGFR was lower than at baseline. Conclusion Long-term treatment of hepatitis B with lowdose (10 mg/day) ADV and LAM can potentially cause renal impairment and hypophosphatemia. We advocate regular monitoring of serum phosphate and evaluation of eGFR, in addition to serum creatinine, in such patients.
Introduction
Hepatitis B virus (HBV) infects more than 350 million people worldwide. Hepatitis B is a leading cause of chronic hepatitis, cirrhosis, and hepatocellular carcinoma (HCC) [1] . The goal of therapy is to reduce HBV replication to limit progressive liver disease and improve the natural history of chronic HBV infection (CHBI) [2] . Oral nucleotide analogs are used for antiviral therapy of patients with CHBI. Lamivudine (LAM) is the first nucleotide analogue indicated for CHBI [3] . However, long-term LAM therapy is associated with emergence of drug-resistant HBV mutation, and relapse of hepatitis [4] [5] [6] [7] . Subsequent studies indicated that adefovir dipivoxil (ADV) alone or in combination with LAM provides effective antiviral therapy in patients with LAM-resistant HBV [8, 9] . However, ADV monotherapy of LAM-resistant HBV resulted in the appearance of virological breakthrough due to acquisition of ADV-resistant mutation [10] . Therefore, the Japanese guidelines recommend the use of the combination of ADV and LAM for patients with LAM-resistant HBV [11] .
Renal impairment is one of the most serious side effects of ADV. Nephrotoxicity associated with ADV is dosedependent. In CHBI phase III trials, significant renal toxicity was not observed during a median follow-up period of 64 weeks in patient treated with ADV at 10 mg/day [12] . However, renal dysfunction associated with long-term use of low-dose ADV has been documented in a few reports published in recent years [13] [14] [15] . Moreover, a few case reports also described hypophosphatemia associated with Fanconi's syndrome in association with the use of ADV at 10 mg/day [14, 16, 17] .
On the other hand, there are only a few studies on the incidence of renal dysfunction and hypophosphatemia during long-term combination therapy of ADV and LAM. In the present study, we investigated the incidence of renal impairment and hypophosphatemia associated with longterm use of ADV-LAM combination in patients with CHBI and defined the characteristics of those patients who developed the above side effects.
Patients and methods

Patients
The study group comprised 292 Japanese patients who were treated with the combination therapy of ADV and LAM between November 2002 and December 2011 at Toranomon Hospital, Tokyo, Japan. Patients were included in this study if they met the following criteria: (1) patients with LAM-refractory CHBI who commenced ADV add-on LAM at Toranomon Hospital; (2) the starting dose of ADV was 10 mg/day; (3) normal renal function at the commencement of ADV (serum creatinine \ 1.2 mg/dl and estimated glomerular filtration rate (eGFR) of C50 ml/min/ 1.73 m 2 ); (4) patients who received the combination therapy for more than 6 months. Furthermore, we excluded patients who had history of treatment with other nucleotide analogs and co-infection with hepatitis C virus or human immunodeficiency virus (HIV).
Study protocol
Patients visited our hospital every 1-3 months after the initiation of ADV treatment, and blood samples were obtained at every visit. We evaluated virological and biochemical markers at the start of ADV and every 6 months thereafter. The eGFR was calculated by the Japanese GFR equation [194 9 Cr 1.094 9 age 0.287 (9 0.739 for females)]. Renal impairment represented a decrease in eGFR to \ 50 ml/min/1.73 m 2 , while hypophosphatemia was defined by serum phosphate level of \ 2.5 mg/dl. The dosing interval of ADV was modified by the attending physician when serum creatinine level increased to [ 1.2 mg/dl. Liver cirrhosis was defined by presence of stage 4 fibrosis on histopathological examination and/or clinical evidence of portal hypertension.
The study was conducted in accordance with the ethical guidelines of the Declaration of Helsinki and approved by the ethics committee of Toranomon Hospital.
Statistical analysis
Descriptive statistics were reported as proportion (%) for categorical variables, and median values (range) for continuous variables. The Mann-Whitney U test was used to compare two continuous variables, and Fisher's exact test or Chi square test was used to compare two categorical variables. The cumulative incidences of renal impairment and hypophosphatemia were calculated using the KaplanMeier method and group data were evaluated using the logrank test. The Cox proportional hazard regression model was used to estimate univariate and multivariate risk factors for renal dysfunction and hypophosphatemia. Wilcoxon rank sum test was used to compare changes in the median values of eGFR and serum phosphate. Statistical significance was defined with two-tailed P value of \ 0.05. Statistical analyses were performed using The Statistical Package for Social Sciences (version11; SPSS, Chicago, IL). Table 1 lists the baseline clinical and laboratory characteristics at the start of ADV. The total duration of the combination therapy of ADV and LAM was 64.3 months (range: 6-118). The median age of the patient was 47 years , and patients were mostly men (78.1 %). Sixtyseven (22.9 %) patients had cirrhosis before starting ADV, and 48 patients (16.4 %) had a history of HCC or had HCC at study entry. Forty-two (14.4 %) patients had diabetes mellitus, and 17 (5.4 %) had arterial hypertension. The median body weight was 63 kg (39.9-92.5), and median BMI was 22.2 kg/m 2 (15.8-36.9) . Baseline eGFR was 85.2 ml/min/1.73 m 2 (51.2-179.9), and phosphate was 3.2 mg/dl (1.6-4.6).
Results
Baseline characteristics
ADV-induced nephrotoxicity
Frequency of renal impairment
Twenty-eight (9.6 %) patients developed renal impairment during the combination therapy. The eGFR decreased 20-30 % from baseline in 67 (22.9 %) patients, 30-50 % in 54 (18.5 %) patients, and [50 % in 5 (1.7 %) patients. Figure 1 displays the cumulative incidence of renal impairment. Figure 1a shows the time to eGFR of \ 50 ml/min/ 1.73 m 2 (i.e., renal impairment). The 1-, 3-, and 5-year cumulative incidence of renal impairment was 1.4, 7.5, and 10.5 %, respectively. Figure 1b shows the time to reduction in eGFR of C30 % from baseline. The 1-, 3-, 5-year cumulative incidence of reduction in eGFR C30 % was 5.9, 16.2, 22.7 %, respectively. We also evaluated renal function using serum creatinine. Serum creatinine increased to more 
(C) Fig. 1 Cumulative incidence of renal impairment and hypophosphatemia. a Cumulative incidence of reduction of eGFR to less than 50 ml/min/1.73 m 2 at 1-, 3-, and 5-years of treatment with ADV and LAM. b Cumulative incidence of reduction of eGFR by C30 % relative to baseline at 1-, 3-, and 5-years of treatment with ADV and LAM. c Cumulative incidence of hypophosphatemia among 269 patients with baseline IP of C2.5 mg/dl than 1.2 mg/dl in 34 (11.6 %) patients during the study period. The 1-, 3-, and 5-year cumulative incidence of serum creatinine of C1.2 mg/dl was 1.4, 6.51, and 11.4 %, respectively. The proportion of patients who developed renal impairment started to increase about 2 years after the commencement of ADV.
Time-course of renal impairment Figure 2a shows serial changes in the median value of eGFR after the addition of ADV to LAM. We excluded from this analysis those patients in whom the dose of ADV was reduced at the point of modification. The eGFR of 264 patients without renal impairment remained stable throughout the study. On the other hand, the eGFR of 28 patients with renal impairment decreased rapidly within about 2 years after the addition of ADV.
Predictive factors for renal impairment
The results of univariate and multivariate analyses, including the hazard ratio for eGFR to \ 50 ml/min/ 1.73 m 2 , are shown in Table 2 . Univariate analysis showed that old age (C 50 years, P \ 0.0001), current cirrhosis (P \ 0.0001), current and/or history of HCC (P = 0.001), history of hypertension (P \ 0.0001), mild renal dysfunction at baseline (eGFR \ 80 ml/min/1.73 m 2 , P = 0.001), and thrombocytopenia (platelet count \ 15 9 10 4 /mm 3 , P = 0.003) were associated with the development of nephrotoxicity. Multivariate analysis indicated that old age (P = 0.006), cirrhosis (P = 0.011), and history of hypertension (P = 0.005) were significant predictors of renal impairment.
Univariate and multivariate analyses were also performed for a fall in eGFR of C30 % relative to baseline. The results of univariate analysis showed that old age (P \ 0.0001), female sex (P = 0.007), small body weight (\ 60 kg, P = 0.002), history of diabetes mellitus (P \ 0.0001), mild renal dysfunction at baseline (P = 0.018), hypo-albuminemia (P = 0.010), and thrombocytopenia (P = 0.007) were associated with decrease in eGFR of C30 % relative to baseline. On the other hand, multivariate analysis identified old age (P \ 0.001), small body weight (P = 0.015), history of diabetes mellitus (P = 0.020), and mild renal dysfunction at baseline (P \ 0.0001) as significant predictors of fall in eGFR of C30 % relative to baseline.
In either case, old age was a significant contributing factor of ADV-induced renal impairment. History of diabetes mellitus and arterial hypertension were also significant predictors.
Effect of modification of ADV dosing interval on renal impairment
Seventeen (5.8 %) patients required modification of the ADV dosing interval because of renal impairment. The ADV dosing interval was changed from 10 mg every day to 10 mg every other day when creatinine increased to C1.2 mg/dl. The clinical characteristics of the 17 patients could be summarized as follows: all were men with a median age of 54 years (35-63), 8 (47.1 %) patients had cirrhosis, 4 (23.5 %) patients had a history of HCC, baseline eGFR was 69.3 ml/min/1.73 m 2 (58.2-89.3), phosphate was 3.3 mg/dl (2.1-3.9), and the median time to modification of ADV dose was 48.5 months (20.7-70.0). Figure 3a shows changes in eGFR and Fig. 3b shows changes in serum phosphate after modification of the ADV dosing interval. The dose modification significantly improved eGFR and serum phosphate as measured at 6 months and 1 year after the modification. Analysis of the long-term courses of eGFR and phosphate in these 17 patients after modification of ADV showed that the median eGFR after 1-, 2-, and 3-years of modification was 53.2, 56.7, 53.9 ml/min/1.73 m 2 , respectively. eGFR remained [ 50 ml/min/1.73 m 2 after modification, but never recovered to baseline level. None of the patients required discontinuation of ADV due to renal impairment.
ADV-induced hypophosphatemia
Frequency of hypophosphatemia Seventy-three (27.1 %) of 269 patients who had normal phosphate at baseline developed hypophosphatemia during the course of the study. Fourteen (19.1 %) of the 73 patients who developed hypophosphatemia continued to show hypophosphatemia until the end of the study. On the other hand, the remaining 59 patients developed transient hypophosphatemia only. The cumulative incidence of hypophosphatemia is shown in Fig. 1c . The 1-, 3-, and 5-year cumulative incidence of hypophosphatemia was 6.8, 20.6, and 26.7 %, respectively. On the other hand, 23 patients had hypophosphatemia at baseline. Seven (30.4 %) of these 23 patients had chronic hypophosphatemia. The phosphate level of 4 (17.4 %) patients reverted spontaneously to normal, while serum phosphate level of the other 12 (52.2 %) patients fluctuated during the study.
Time-course of hypophosphatemia Figure 2b shows changes in the median serum level of phosphate after the addition of ADV to LAM. We excluded from this analysis those patients in whom the dose of ADV was reduced at the point of modification. The median phosphate level decreased gradually after the addition of ADV in patients who subsequently developed hypophosphatemia.
Predictive factors for hypophosphatemia Table 3 shows the results of univariate and multivariate analyses, including hazard ratio, of the factors associated with a fall in serum phosphate level to \ 2.5 mg/dl. Patients with baseline serum phosphate of \ 2.5 mg/dl (n = 23) were excluded from the analysis. Univariate analysis showed that male sex (P = 0.002), cirrhosis (P = 0.012), current and/or history of HCC (P = 0.012), and low baseline phosphate level (P \ 0.0001) correlated with hypophosphatemia. On the other hand, multivariate analysis identified male sex (P = 0.016), current and/or history of HCC (P = 0.020), and low baseline serum phosphate level (P \ 0.0001) as significant determinants of ADV-induced hypophosphatemia.
Further analysis showed that decreases in eGFR of more C30 % relative to the baseline value in 2.5 years correlated significantly with hypophosphatemia (P = 0.007).
Effect of modification of ADV dosing interval on hypophosphatemia and liver function
The median serum phosphate level after 1-, 2-, and 3-years of modification of ADV dose was 2.9, 3.1, and 3.0 mg/dl, respectively. Serum phosphate level fluctuated even after the dose modification. We also analyzed changes in serum ALT and HBV-DNA. After ADV dose modification, serum ALT level decreased to within the normal range (ALT \ 40 IU/L) in 16 of 17 patients. Although serum ALT level of the remaining single case increased transiently after the modification, it normalized 1 year later. The HBV-DNA level was below the detection level at ADV dose modification in 14 of the 17 Table 4 lists the clinical features of these patients. Three of these patients complained of bone pain during treatment. They had markedly elevated alkaline phosphatase (ALP) and low serum uric acid (UA) levels during the combination therapy. Their serum creatinine level remained normal, but their eGFR decreased relative to baseline. Figure 4 provides a summary of the clinical course of cases 1 and 10. Case 1 was a 63-year-old woman with HBeAg-positive liver cirrhosis. She was first treated with LAM for chronic hepatitis, but ADV was added 17 months later due to the development of LAM resistance. The laboratory data (serum phosphate, ALP, UA and creatinine) were within normal ranges at baseline, and she had no other health problems. Continuous treatment with ADV for about 3 years resulted in increase in ALP level and decrease in UA and serum phosphate. After 4.5 years, she developed lumbago and right ankle pain. Blood tests showed ALP of 1102 IU/ml, UA of 1.2 mg/dl, and serum phosphate of 0.8 mg/dl. Other laboratory tests demonstrated metabolic acidosis, aminoaciduria, low tubular reabsorption of phosphate (34.8 %; normal value 85-98 %), and high fractional excretion of uric acid (47.6 %; normal value 4-14 %). These results indicated generalized dysfunction of the proximal renal tubules. A technetium bone scan showed increased uptake in bilateral ribs, carpal bones, lumbar spine, and bilateral calcaneus. She was diagnosed with acquired Fanconi's syndrome with hypophosphatemic osteomalacia associated with ADV therapy. ADV was discontinued and replaced with entecavir (ETV) while hypophosphatemia was treated with oral phosphate. Three months after cessation of ADV and oral phosphate supplementation, the patient reported symptomatic improvement and blood tests showed normalization of phosphate level and low ALP level.
Case 10 was a 31-year-old man with HBeAg-positive liver cirrhosis. He was also first treated with LAM, and ADV was added on 16 months later. The laboratory data were within the normal ranges at baseline. Treatment for 1.5 year with ADV resulted in decrease in serum phosphate and UA, and 4-year treatment increased ALP level. After 7 years, the right metatarsal bone broke in an accident.
After 9 years of treatment, blood tests showed serum phosphate of 1.3 mg/dl. Detailed clinical examination was conducted at that stage. Other laboratory tests showed aminoaciduria, low tubular reabsorption of phosphate (65.5 %), and high fractional excretion of uric acid (19.1 %). A technetium bone scan showed increased uptake in bilateral ribs, bilateral ankles, tarsal bones, and right metatarsal. He was also diagnosed with acquired Fanconi's syndrome and hypophosphatemic osteomalacia associated with ADV therapy. ADV dosing interval was changed from 10 mg every day to 10 mg every other day, and oral phosphate supplementation and calcitriol were added to the treatment. Treatment for 2 months resulted in improvement of symptoms and normalization of phosphate level.
Discussion
Renal impairment is one of the most serious adverse effects of ADV. The following mechanism is considered to explain ADV-induced nephrotoxicity: the human organic anion transporter-1 (hOAT1) is a renal membrane protein expressed at the basolateral membrane of the proximal tubule cells. hOAT1 can efficiently transport cyclic nucleoside phosphonate, and thus contribute to ADV nephrotoxicity by accumulation of the drug in renal proximal tubules [18, 19] .
Previous studies indicated that the ADV-related nephrotoxicity is dose-dependent [12] . In a large-scale clinical trial, 8 % of patients treated with 30 mg/day ADV for 48 weeks had high serum creatinine (C0.5 mg/dl), relative to baseline. On the other hand, none of the patients treated with 10 mg/day ADV showed increase in creatinine (C0.5 mg/dl), relative to baseline [20] . Thus, ADV at a dose of 10 mg/day has been used previously for the treatment of patients with CHBI. However, renal dysfunction has been reported even after the use of ADV at this dose, especially after long-term administration [13] [14] [15] . For example, in a study of the 10 mg ADV combined with LAM, serum creatinine increased in 38 % of patients following median treatment duration of 38 months [14] . In another retrospective study of 687 patients, during a median treatment period of 27 months, 10.5 % of patients developed renal impairment, which was defined as a decrease in eGFR of more than 20 % relative to the baseline [15] . In our study, 9.6 % of patients developed renal impairment during a median treatment duration of 64.3 months. Our results also showed that 20.2 % of the patients exhibited more than 30 % decrease in eGFR, and a much larger proportion (43.2 %) of the patients showed more than 20 % decrease in eGFR. These rates are higher than those reported previously. Furthermore, as shown in Fig. 2a , patients with rapid falls in eGFR within the first 2 years of treatment should be carefully monitored for any renal dysfunction. Based on the results of our study, it seems that longer dosing period is associated with higher incidence of renal dysfunction.
We also analyzed the risk factors of renal impairment defined by a decrease in eGFR to less than 50 ml/min/ 1.73 m 2 . Ha et al. [13] reported that age [50 years, mild renal impairment at baseline, hypertension and/or diabetes mellitus, and male sex were significant predictors of renal impairment characterized by decrease in eGFR of C20 % relative to baseline. Furthermore, Yu et al. [15] also reported that age C50 years was a significant predictor of renal dysfunction in those patients treated with ADV. In our study, age was also identified as a significant and independent determinant of the primary endpoint, together with liver cirrhosis and history of arterial hypertension. Considered together, these data indicate that care should be taken when ADV-based therapy is used for elderly patients with CHBI.
Cross-sectional studies have demonstrated a decline in GFR with age [21, 22] . Moreover, hypertension and diabetes mellitus are also reported to worsen the rate of decline of renal function [23] [24] [25] . Renal failure is common and often severe in patients with cirrhosis due to the activation of various vasoconstrictor systems, including the renin-angiotensin system and the sympathetic nervous system [26] . Taken together, eGFR is more likely to decrease during ADV therapy in patients with older age, hypertension, diabetes mellitus, cirrhosis, mild renal dysfunction at baseline.
ADV-induced proximal tubule failure can lead to hypophosphatemia. In a randomized clinical control trial using 120 mg/day ADV for treatment of patients with HIV, hypophosphatemia occurred in 50 % of patients after 48 weeks and in 61 % of patients after 72 weeks of ADV treatment [27] . On the other hand, in another study using 10 mg/day ADV for patients with CHBI, there was no overall change in serum phosphorus level during the 96-week study period [28] . However, in recent years, several reports have described the development of hypophosphatemia in patients treated with ADV at a daily dose of 10 mg [14, 29] . In our study, 27.1 % of patients developed hypophosphatemia during the combination therapy. Although 21.9 % of patients developed transient hypophosphatemia, 5.2 % of patients who had normal phosphate level at baseline developed persistent hypophosphatemia. In this regard, one previous study reported that approximately 2 % of hospitalized patients had hypophosphatemia [30] . Collectively, the above results and our findings indicate that ADV-based treatment is associated with a high incidence of hypophosphatemia. Tamori et al. [14] reported that serum phosphate level decreased to less than 2.5 mg/ml in 16.2 % of their patients during the 38-month combination therapy. Gara et al. [29] reported that 14 % of their patients treated with nucleotide analog therapy (10 mg/day ADV combined with 100 mg/day LAM, or 300 mg/day tenofovir monotherapy) developed persistent hypophosphatemia. Analysis of our data identified male sex, presence and/or history of HCC, and low serum phosphate level at baseline as significant determinants of hypophosphatemia. Furthermore, a decrease in eGFR by C30 % relative to baseline within 2.5 years was also associated with the development of hypophosphatemia.
Hepatic insufficiency is associated with impairment in 25-hydroxylation of vitamin D in the liver, which can lead to reduced synthesis of 1, 25 (OH) 2D3, with subsequent worsening of hypophosphatemia based on reduced intestinal absorption of phosphorus [31, 32] . In our study, 73 % of patients with HCC had liver cirrhosis, and the presence and/or history of HCC was a predictor of hypophosphatemia. Another mechanism of hypophosphatemia is protein and calorie malnutrition, which is a common feature of chronic liver disease. Furthermore, invasive treatment of HCC may itself cause hypophosphatemia. The present study also analyzed the relation between gender and hypophosphatemia. In a study that enrolled more than 4500 community-dwelling Italians of broadly diverse age, serum phosphorus levels were similar in males and females until the age of 45 years [33] . Interestingly, serum phosphate level increased in females aged between 45 and 54 years but fell after 55 years of age. The increase in serum phosphate level in females is probably related to menstrual status [33] . In the present study, serum phosphate level was higher in females than in males at baseline (3.51 vs. 3.18, P \ 0.0001). Thus, male sex was a significant determinant of hypophosphatemia. These findings call for careful monitoring of serum phosphate level in patients treated with ADV, especially male patients, patients with HCC, and patients with renal dysfunction.
Several studies described the development of Fanconi's syndrome and subsequent hypophosphatemic osteomalacia in patients treated with 10 mg/day ADV [14, 16, 17] . Fanconi's syndrome is characterized by generalized transport defect in the proximal tubules, leading to renal losses of glucose, phosphate, uric acid, amino acids, bicarbonate, and other organic compounds [34] . Severe hypophosphatemia seems to cause inadequate mineralization of bone matrix, with subsequent osteomalacia [35, 36] . The electrolyte imbalance and osteomalacia cause symptoms of muscle weakness, fatigue, ostealgia, and bone fractures [37] . Acquired renal tubular defect resulting in Fanconi's syndrome have been described in association with many exogenous agents, including valproate, aminoglycosides, tetracycline, and acyclic nucleoside phosphonates [34] .
Various approaches have been used for the treatment of osteomalacia associated with Fanconi's syndrome. Clarke et al. [38] reported successful treatment of osteomalacia associated with acquired Fanconi's syndrome with calcium, phosphate and vitamin D, regardless of the underlying cause of the disease. Eight cases of Fanconi's syndrome with ADVrelated hypophosphatemic osteomalacia were reported in the past 5 years [14, 16, 17, [39] [40] [41] . Three of the 8 patients were treated with oral phosphate only; while 3 other patients received oral phosphate and vitamin D, and one patient was treated with the combination of oral phosphate, vitamin D and calcium. In all cases, treatment increased serum phosphate level and improved musculoskeletal symptoms. Similar to the eight cases reported in the literature, our 2 patients showed normalization of phosphate level and symptomatic improvement after treatment. Treatment with oral phosphate for ADV-related hypophosphatemic osteomalacia is considered effective.
We also examined the clinical characteristics of the 14 patients who developed persistent hypophosphatemia. Three of the 14 patients developed ostealgia during the treatment. Patients 1 and 10 were diagnosed with acquired Fanconi's syndrome with subsequent hypophosphatemic osteomalacia. Although we could not confirm the diagnosis of Fanconi's syndrome in patient 2 because she was transferred to another hospital, she was considered to have developed Fanconi's syndrome based on the clinical course. Despite persistent hypophosphatemia, serum creatinine remained within the normal range. In addition, 6 of the 14 patients also had low eGFR (C30 % decrease relative to baseline), and two patients with Fanconi's syndrome showed C40 % decrease in eGFR, relative to baseline. Based on the above features, patients can develop marked hypophosphatemia and serious complications, such as Fanconi's syndrome, following significant fall in eGFR, irrespective of the level of serum creatinine. In the three patients who developed Fanconi's syndrome, a gradual increase in serum ALP level and simultaneous fall in serum uric acid were noted more than one year before the appearance of ostealgia. Based on the above findings, we recommend reducing the dose or changing medications to other nucleotide analogues in patients who develop hypouricemia, hyper-ALPemia, hypophosphatemia, and low eGFR, to avoid the development of ADV-induced Fanconi's syndrome.
In our study, the dosing interval of ADV was modified by the attending physician following increase in serum creatinine level. Seventeen (5.8 %) patients required such modification, their eGFR and serum phosphate showed significant improvement at 6 and 12 months after the modification, in agreement with previous reports [13, 42] . However, the modification in ADV dosing interval from 10 mg every day to every other day neither affected HBV-DNA level nor the antiviral effect. Therefore, the ADV dose should be modified in patients who show decrease in eGFR and/or serum phosphate.
In conclusion, our results showed that even at low dose of 10 mg/day, long-term combination therapy of ADV and LAM can cause renal impairment and hypophosphatemia, and lead to Fanconi's syndrome in a subgroup of patients. ADV-based treatment tends to reduce eGFR and serum phosphate especially in elderly male patients and those with HCC. We recommend regular monitoring of serum phosphate and evaluation of eGFR, in addition to serum creatinine, in patients treated with ADV. Suspicion of Fanconi's syndrome requires early reduction of ADV dose or switching to other antiviral agents.
